Sun's 1st-qtr FY 2008 sales rise 66% to $246M

India's Sun Pharmaceutical Industries says that, in the three months ending June 30, 2008, its consolidated net sales increased 66% year-on-year to 10.42 billion rupees ($245.9 million), as US generics sales increased 206% to $108.0 million while revenue from elsewhere grew 134%.

During the period, which is the first quarter of the firm's 2009 financial year, operating margin increased to 49%, while net profit jumped 121% to 5.01 billion rupees.

Sales of domestic branded formulations totaled 4.29 billion rupees, up 17% over the same quarter last year, contributing 40% of total revenue. Sun says it holds 3.4% market share in its highly competitive home market, according to the latest IMS ORG report, achieving seven key products launches during the quarter.